Main description:

This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Contents:

.-1 Targeted Cancer Therapy: History and Development of Immunotoxins

.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective

.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins

.-4 Cell Signaling and Resistance to Immunotoxins

.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms

.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins

.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy

.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

.-9 Therapeutic Impact of Immune Responses in Cancer

.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy

.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

.-9 Therapeutic Impact of Immune Responses in Cancer

.-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy

.-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

.-9 Therapeutic Impact of Immune Responses in Cancer